Search

ISSN 1462-8902

1. 3‐carboxy‐4‐methyl‐5‐propyl‐2‐furanpropanoic acid (CMPF) prevents high fat diet‐induced insulin resistance via maintenance of hepatic lipid homeostasis. Issue 1 (6th September 2018)

Authors:
Mohan, Haneesha; Brandt, Sydney L.; Kim, Ja Hyun; Wong, Frances; Lai, Mi; Prentice, Kacey J.; Al Rijjal, Dana; Magomedova, Lilia; Batchuluun, Battsetseg; Burdett, Elena; Bhattacharjee, Alpana; Cummins, Carolyn L.; Belsham, Denise D.; Cox, Brian; Liu, Ying; Wheeler, Michael B.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 21:Issue 1(2019)
Page Start:
61
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A 12‐week, randomized, double‐blind, placebo‐controlled, four‐arm dose‐finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes. Issue 4 (11th December 2019)

Authors:
Halvorsen, Yuan‐Di; Walford, Geoffrey; Thurber, Tara; Russell, Heidy; Massaro, Monica; Freeman, Mason W.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 22:Issue 4(2020)
Page Start:
566
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD‐8). Issue 5 (19th February 2016)

Authors:
Dungan, K. M.; Weitgasser, R.; Perez Manghi, F.; Pintilei, E.; Fahrbach, J. L.; Jiang, H. H.; Shell, J.; Robertson, K. E.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 18:Issue 5(2016)
Page Start:
475
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. A 24‐week, randomized, double‐blind, active‐controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults. Issue 10 (30th June 2019)

Authors:
Halvorsen, Yuan‐Di; Lock, John P.; Zhou, Wenjiong; Zhu, Fang; Freeman, Mason W.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 21:Issue 10(2019)
Page Start:
2248
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. A 4D view on insulin secretory granule turnover in the β‐cell. (September 2017)

Authors:
Müller, Andreas; Mziaut, Hassan; Neukam, Martin; Knoch, Klaus‐Peter; Solimena, Michele
Other Names:
Cerasi Erol guestEditor.; Accili Domenico guestEditor.; Ahrén Bo guestEditor.; Boitard Christian guestEditor.; Seino Susumu guestEditor.; Thorens Bernard guestEditor.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 19(2017)Supplement 1
Page Start:
107
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. A 52‐week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add‐on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone. Issue 6 (6th April 2018)

Authors:
Jung, Chan‐Hee; Rhee, Eun‐Jung; Lee, Won‐Young; Min, Kyung Wan; Shivane, Vyankatesh K.; Sosale, Aravind R.; Jang, Hak Chul; Chung, Choon Hee; Nam‐Goong, Il Seong
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 20:Issue 6(2018)
Page Start:
1535
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. A 52‐week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N‐ISM study. Issue 3 (8th January 2021)

Authors:
Kitazawa, Masaru; Katagiri, Takashi; Suzuki, Hiromi; Matsunaga, Satoshi; H Yamada, Mayuko; Ikarashi, Tomoo; Yamamoto, Masahiko; Furukawa, Kazuo; Iwanaga, Midori; Hatta, Mariko; Fujihara, Kazuya; Yamada, Takaho; Tanaka, Shiro; Sone, Hirohito
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 23:Issue 3(2021)
Page Start:
811
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. A 96‐week, double‐blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults. Issue 1 (23rd October 2022)

Authors:
Halvorsen, Yuan‐Di; Lock, John Paul; Frias, Juan P.; Tinahones, Francisco José; Dahl, Dominik; Conery, Annie L.; Freeman, Mason W.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 25:Issue 1(2023)
Page Start:
293
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. A 96‐week, multinational, randomized, double‐blind, parallel‐group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes. Issue 11 (8th August 2019)

Authors:
Halvorsen, Yuan‐Di C.; Walford, Geoffrey A.; Massaro, Joseph; Aftring, Robert P.; Freeman, Mason W.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 21:Issue 11(2019)
Page Start:
2496
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗